Gellert Balazs Karvaly
Overview
Explore the profile of Gellert Balazs Karvaly including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
17
Citations
36
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Feher A, Vincze I, Rudge J, Domjan G, Vasarhelyi B, Karvaly G
Diagnostics (Basel)
. 2024 Sep;
14(17).
PMID: 39272725
Our aim was to compare the performance of complementary clinical laboratory approaches to monitoring exposure to apixaban and rivaroxaban, the most prescribed direct-acting oral anticoagulants (DOAC's): an automated commercial anti-Xa...
2.
Karvaly G, Vasarhelyi B
Pharmaceutics
. 2024 Jun;
16(6).
PMID: 38931913
The philosophy, practice, and clinical impact of therapeutic drug monitoring (TDM) has changed profoundly with the appearance of widely available and, in a technical sense, commonly applicable modeling, simulation, and...
3.
Gulyas E, Horvath I, Engh M, Bunduc S, Dembrovszky F, Fehervari P, et al.
Sci Rep
. 2024 Apr;
14(1):7793.
PMID: 38565898
An estimated 70% of critically ill patients receive antibiotics, most frequently beta-lactams. The pharmacokinetic properties of these substances in this patient population are poorly predictable. Therapeutic drug monitoring (TDM) is...
4.
Karvaly G, Vincze I, Neely M, Zatroch I, Nagy Z, Kocsis I, et al.
Pharmaceutics
. 2024 Mar;
16(3).
PMID: 38543252
Population pharmacokinetic (pop-PK) models constructed for model-informed precision dosing often have limited utility due to the low number of patients recruited. To augment such models, an approach is presented for...
5.
Holub L, Szabo B, Zavorszky L, Humpfner R, Andreka P, Karvaly G, et al.
Orv Hetil
. 2024 Mar;
165(11):403-415.
PMID: 38493416
No abstract available.
6.
Kophazi L, Karpathi I, Kesztyus V, Holndonner-Kirst E, Gulyas E, Karvaly G, et al.
Orv Hetil
. 2023 May;
164(18):702-712.
PMID: 37149846
The recent developments in intensive care have resulted in improved survival rates of patients treated with acute organ deficiency. As a consequence, the rate of those who survive the acute...
7.
Kollo Z, Garami M, Vincze I, Vasarhelyi B, Karvaly G
Pharmaceutics
. 2023 Jan;
15(1).
PMID: 36678867
Orally administered, small-molecule anticancer drugs with tumor-specific cellular protein targets (OACD) have revolutionized oncological pharmacotherapy. Nevertheless, the differences in exposure to these drugs in the systemic circulation and extravascular fluid...
8.
Karvaly G, Vincze I, Balogh A, Kollo Z, Bodor C, Vasarhelyi B
Molecules
. 2022 Jul;
27(15).
PMID: 35897942
Ibrutinib (IBR) is an oral anticancer medication that inhibits Bruton tyrosine kinase irreversibly. Due to the high risk of adverse effects and its pharmacokinetic variability, the safe and effective use...
9.
Vincze I, Czermann R, Nagy Z, Kovacs M, Neely M, Farkas R, et al.
J Clin Med
. 2022 Jul;
11(14).
PMID: 35887904
Severe community-acquired pneumonia (CAP) is a condition that frequently requires intensive care and, eventually, can cause to death. Piperacillin/tazobactam antibiotic therapy is employed as an empiric intravenous regimen, in many...
10.
Kovacs K, Karvaly G, Farkas R, Vasarhelyi B
Orv Hetil
. 2022 Mar;
163(13):500-505.
PMID: 35339992
Összefoglaló. Régóta folynak kutatások olyan újabb biomarkerek azonosítására, amelyek segítik a krónikusan progrediáló, úgynevezett civilizációs betegségek - például cardiovascularis kórképek, vesefunkció-beszűkülés - korai felismerését. Az aszimmetrikus és a szimmetrikus dimetil-arginin...